CLIMB BIO, INC. Investment Income, Interest
CLIMB BIO, INC. (CLYM) reported Investment Income, Interest of $1.85 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- CLIMB BIO, INC. investment income, interest for the quarter ending 2026-06-30 was $1.85M, a 14.63% decline year-over-year.
- CLIMB BIO, INC. investment income, interest for the quarter ending 2026-03-31 was $1.51M, a 33.80% decline year-over-year.
- CLIMB BIO, INC. investment income, interest for the quarter ending 2025-12-31 was $1.83M, a 27.57% decline year-over-year.
- CLIMB BIO, INC. investment income, interest for the quarter ending 2025-09-30 was $2.04M, a 26.86% decline year-over-year.
- CLIMB BIO, INC. investment income, interest for fiscal 2025 was $8.32M, a 2.35% increase from fiscal 2024.
- CLIMB BIO, INC. investment income, interest for fiscal 2024 was $8.13M.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.85M 10-Q · filed 2026-08-06 | $3.37M 10-Q · filed 2026-08-06 | $5.20M derived: sum of 3 quarters · filed 2026-08-06 | $7.23M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.51M 10-Q · filed 2026-05-07 | $3.34M derived: sum of 2 quarters · filed 2026-05-07 | $5.38M derived: sum of 3 quarters · filed 2026-05-07 | $7.55M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $1.83M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $3.86M derived: sum of 2 quarters · filed 2026-03-05 | $6.04M derived: sum of 3 quarters · filed 2026-08-06 | $8.32M 10-K · filed 2026-03-05 |
| 2025-09-30 | $2.04M 10-Q · filed 2025-11-06 | $4.21M derived: sum of 2 quarters · filed 2026-08-06 | $6.50M 10-Q · filed 2025-11-06 | $9.02M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $2.17M 10-Q · filed 2026-08-06 | $4.46M 10-Q · filed 2026-08-06 | $6.98M derived: sum of 3 quarters · filed 2026-08-06 | $9.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $2.29M 10-Q · filed 2026-05-07 | $4.81M derived: sum of 2 quarters · filed 2026-05-07 | $7.59M derived: sum of 3 quarters · filed 2026-05-07 | $9.08M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $2.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | $5.31M derived: sum of 2 quarters · filed 2026-03-05 | $6.79M derived: sum of 3 quarters · filed 2026-03-05 | $8.13M 10-K · filed 2026-03-05 |
| 2024-09-30 | $2.79M 10-Q · filed 2025-11-06 | $4.27M derived: sum of 2 quarters · filed 2025-11-06 | $5.61M 10-Q · filed 2025-11-06 | |
| 2024-06-30 | $1.49M 10-Q · filed 2025-08-12 | $2.83M 10-Q · filed 2025-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Nuvectis Pharma, Inc. (NVCT) | United States | $0.705B | -17.53 |
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |